Mein Gene is a leading genetic testing platform company in China, focusing on consumer-grade genetic testing and cancer screening services. Since its establishment in 2016 to December 31, 2023, the company has carried out more than 19 million genetic tests. According to Frost & Sullivan data, as of December 31, 2021, the company is the largest consumer-grade genetic testing platform in China based on the cumulative number of tests carried out; according to the number of tests carried out in 2020, the company is also the largest cancer screening genetic testing platform in China. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis to meet the growing demand of consumers for preventive medicine. With an advanced integrated technology platform system and market-leading process automation standards, the company's high-throughput testing platform can process 50,000 samples per day, which is the greatest capacity in the industry. At the same time, the company is actively exploring potential applications of genetic technology in health management, precision medicine and new drug development. As of December 31, 2023, the company cooperated with more than 1,800 healthcare institutions in more than 340 cities in China. In addition, the company has established strategic cooperation with a number of e-commerce and online healthcare platforms, so that services can be extended to more regions, and more people can pass genetic testing to better manage their health. Meiyin Gene is committed to unlocking genetic mysteries and protecting human health with advanced genetic testing technology and inclusive genetic testing services.
No Data
No Data